Journal of Global Antimicrobial Resistance (Jun 2020)

Prediction of trimethoprim/sulfamethoxazole resistance in community-onset urinary tract infections

  • Madeline DeMarsh,
  • P. Brandon Bookstaver,
  • Caroline Gordon,
  • Juanne Lim,
  • Nicole Griffith,
  • Nicole K. Bookstaver,
  • Julie Ann Justo,
  • Joseph Kohn,
  • Majdi N. Al-Hasan

Journal volume & issue
Vol. 21
pp. 218 – 222

Abstract

Read online

Objectives: This study aimed to predict trimethoprim/sulfamethoxazole (SXT) resistance in patients with community-onset urinary tract infection (UTI) due to Enterobacteriaceae based on patient-specific risk factors. Methods: This was a retrospective case–control study in Prisma Health facilities in central South Carolina, USA, including three community hospitals, affiliated emergency departments and ambulatory clinics, including adult patients with community-onset UTI due to Enterobacteriaceae (1 April 2015 to 29 February 2016). Multivariate logistic regression was used to examine risk factors for SXT resistance. Results: Among 351 unique patients with community-onset UTI, 71 (20.2%) had SXT-resistant Enterobacteriaceae urinary isolates. Overall, median age was 64 years and 252 (71.8%) were female. A multivariate model identified prior urinary infection/colonisation with SXT-resistant Enterobacteriaceae (OR = 8.58, 95% CI 3.92–18.81; P < 0.001) and SXT use within past 12 months (OR = 2.58, 95% CI 1.13–5.89; P = 0.02) as predictors of SXT resistance among urinary isolates. Most patients with UTI (285; 81.2%) had no risk factors for SXT resistance. SXT resistance rates increased from 13% in the absence of risk factors to 31% in patients with prior SXT use, 66% in those with prior urinary infection/colonisation with SXT-resistant Enterobacteriaceae and 73% in the presence of both risk factors. Conclusion: SXT resistance in Enterobacteriaceae urinary isolates may be predicted based on prior urine culture results and SXT use within the previous year. Utilisation of a patient-specific antibiogram may allow empirical SXT use in patients with community-onset UTI in the absence of risk factors for resistance.

Keywords